ABSTRACT
La hiperhidrosis se caracteriza por excesiva sudoración, habitualmente secundaria a disfunción autonómica con hipersecreción de las glándulas sudoríparas ecrinas. La hiperhidrosis primaria focal es la forma más frecuente, y afecta axilas, palmas, plantas y/o cara. Frecuentemente genera un gran impacto en la calidad de vida y en la actividad social. Su tratamiento es complejo. Los antitranspirantes tópicos son recomendados en primer lugar en la mayoría de casos de hiperhidrosis leve. Múltiples ensayos clínicos y estudios prospectivos avalan la eficacia y tolerabilidad de los anticolinérgicos orales y tópicos. En casos moderado/graves, el glicopirronio tópico, el cual ha sido evaluado en al menos 8 ensayos clínicos con más de 2.000 pacientes en total, podría ser considerado la primera línea farmacológica en la hiperhidrosis axilar mal controlada con antitranspirantes tópicos; seguido por inyecciones de toxina botulínica, sistemas de microondas y por anticolinérgicos orales. En este artículo revisamos el rol de los anticolinérgicos tópicos en el manejo de la hiperhidrosis focal en adultos y niños.(AU)
Hyperhidrosis, or excessive sweating, is characterized by overactivity of the eccrine sweat glands, usually associated with dysfunction of the autonomic nervous system. Primary focal hyperhidrosis is the most common form and can affect the axillae, palms, soles, and/or face, often leading to significantly impaired quality of life and social functioning. Treatment is complex. Topical antiperspirants are normally recommended as the first-line treatment for mild hyperhidrosis. Multiple clinical trials and prospective studies support the efficacy and tolerability of oral and topical anticholinergics in the management of hyperhidrosis. Topical glycopyrronium, which has been investigated in at least 8 clinical trials enrolling more than 2000 patients, is probably the first-line pharmacological treatment for axillary hyperhidrosis in patients with moderate to severe disease poorly controlled with topical antiperspirants. Second-line treatments include botulinum toxin injections, microwave treatment, and oral anticholinergics. We review the use of topical anticholinergics in the management of focal hyperhidrosis in adults and children.(AU)
Subject(s)
Humans , Male , Female , Child , Adolescent , Young Adult , Adult , Cholinergic Antagonists/administration & dosage , Hyperhidrosis/drug therapy , Glycopyrrolate , Iontophoresis , Botulinum Toxins, Type A , Dermatology , Skin DiseasesABSTRACT
La hiperhidrosis se caracteriza por excesiva sudoración, habitualmente secundaria a disfunción autonómica con hipersecreción de las glándulas sudoríparas ecrinas. La hiperhidrosis primaria focal es la forma más frecuente, y afecta axilas, palmas, plantas y/o cara. Frecuentemente genera un gran impacto en la calidad de vida y en la actividad social. Su tratamiento es complejo. Los antitranspirantes tópicos son recomendados en primer lugar en la mayoría de casos de hiperhidrosis leve. Múltiples ensayos clínicos y estudios prospectivos avalan la eficacia y tolerabilidad de los anticolinérgicos orales y tópicos. En casos moderado/graves, el glicopirronio tópico, el cual ha sido evaluado en al menos 8 ensayos clínicos con más de 2.000 pacientes en total, podría ser considerado la primera línea farmacológica en la hiperhidrosis axilar mal controlada con antitranspirantes tópicos; seguido por inyecciones de toxina botulínica, sistemas de microondas y por anticolinérgicos orales. En este artículo revisamos el rol de los anticolinérgicos tópicos en el manejo de la hiperhidrosis focal en adultos y niños.(AU)
Hyperhidrosis, or excessive sweating, is characterized by overactivity of the eccrine sweat glands, usually associated with dysfunction of the autonomic nervous system. Primary focal hyperhidrosis is the most common form and can affect the axillae, palms, soles, and/or face, often leading to significantly impaired quality of life and social functioning. Treatment is complex. Topical antiperspirants are normally recommended as the first-line treatment for mild hyperhidrosis. Multiple clinical trials and prospective studies support the efficacy and tolerability of oral and topical anticholinergics in the management of hyperhidrosis. Topical glycopyrronium, which has been investigated in at least 8 clinical trials enrolling more than 2000 patients, is probably the first-line pharmacological treatment for axillary hyperhidrosis in patients with moderate to severe disease poorly controlled with topical antiperspirants. Second-line treatments include botulinum toxin injections, microwave treatment, and oral anticholinergics. We review the use of topical anticholinergics in the management of focal hyperhidrosis in adults and children.(AU)
Subject(s)
Humans , Male , Female , Child , Adolescent , Young Adult , Adult , Cholinergic Antagonists/administration & dosage , Hyperhidrosis/drug therapy , Glycopyrrolate , Iontophoresis , Botulinum Toxins, Type A , Dermatology , Skin DiseasesABSTRACT
Hyperhidrosis, or excessive sweating, is characterized by overactivity of the eccrine sweat glands, usually associated with dysfunction of the autonomic nervous system. Primary focal hyperhidrosis is the most common form and can affect the axillae, palms, soles, and/or face, often leading to significantly impaired quality of life and social functioning. Treatment is complex. Topical antiperspirants are normally recommended as the first-line treatment for mild hyperhidrosis. Multiple clinical trials and prospective studies support the efficacy and tolerability of oral and topical anticholinergics in the management of hyperhidrosis. Topical glycopyrronium, which has been investigated in at least 8 clinical trials enrolling more than 2000 patients, is probably the first-line pharmacological treatment for axillary hyperhidrosis in patients with moderate to severe disease poorly controlled with topical antiperspirants. Second-line treatments include botulinum toxin injections, microwave treatment, and oral anticholinergics. We review the use of topical anticholinergics in the management of focal hyperhidrosis in adults and children.
Subject(s)
Botulinum Toxins, Type A , Hyperhidrosis , Adult , Child , Humans , Antiperspirants/therapeutic use , Cholinergic Antagonists/therapeutic use , Quality of Life , Prospective Studies , Sympathectomy , Hyperhidrosis/drug therapyABSTRACT
El ligamento colateral medial (LCM) de la rodilla es una estructura ligamentosa muy frecuentemente lesionada. La calcificación del LCM es muy infrecuente, benigna, relacionada con desórdenes metabólicos y es consecuencia del depósito de hidroxiapatita de calcio en la región periarticular. El cuadro clínico, histológico y radiológico de la tendinitis calcificante está definido y la etiología es multifactorial. El tratamiento es inicialmente conservador, y si fracasara, intervencionista, siendo la cirugía el último escalón terapéutico. Existen muy pocos reportes en la literatura, estando publicados apenas 10 casos/series de casos. Es importante diferenciarlo del signo y/o síndrome de Pellegrini-Stieda, donde el antecedente traumático es fundamental para diagnosticarlo.El caso clínico es el de una mujer de 64 años en quien presentamos el tratamiento de la calcificación del LCM mediante ondas de choque más iontoforesis, reportamos la efectividad del tratamiento en el manejo del dolor y la calcificación y realizamos una somera revisión sobre el tema.(AU)
The medial collateral ligament (MCL) of the knee is a commonly injured ligament structure. Calcification of the MCL is very infrequent, benign, related to metabolic disorders and is a consequence of the deposition of calcium hydroxyapatite in the periarticular region. The clinical, histological and radiological picture of calcific tendonitis is defined and the etiology is multifactorial. Treatment is initially conservative and if it fails, interventionist; surgery being the last therapeutic step. There are very few reports in the literature, with only 10 cases/case series published. It is important to differentiate it from the PellegriniStieda sign and/or syndrome, where the traumatic history is essential to diagnose it.The clinical case is that of a 64-year-old woman in whom we present the treatment of calcification of the MCL using radial electro shock wave therapy plus iontophoresis, we report the effectiveness of the treatment in the management of pain and calcification, and we carry out a brief review on the subject.(AU)
Subject(s)
Humans , Female , Aged , Medial Collateral Ligament, Knee , Knee , Knee Injuries , High-Energy Shock Waves , Iontophoresis , Calcinosis , Rehabilitation , Inpatients , Physical ExaminationABSTRACT
The medial collateral ligament (MCL) of the knee is a commonly injured ligament structure. Calcification of the MCL is very infrequent, benign, related to metabolic disorders and is a consequence of the deposition of calcium hydroxyapatite in the periarticular region. The clinical, histological and radiological picture of calcific tendonitis is defined and the etiology is multifactorial. Treatment is initially conservative and if it fails, interventionist; surgery being the last therapeutic step. There are very few reports in the literature, with only 10 cases/case series published. It is important to differentiate it from the Pellegrini-Stieda sign and/or syndrome, where the traumatic history is essential to diagnose it. The clinical case is that of a 64-year-old woman in whom we present the treatment of calcification of the MCL using radial electro shock wave therapy plus iontophoresis, we report the effectiveness of the treatment in the management of pain and calcification, and we carry out a brief review on the subject.
